Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.35 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL909752 | 1.00 | KMT2A (0.38) | KMT2AMEN1MEP1BRAPGEF4LMNA | |
| SCHEMBL909187 | 1.00 | KMT2A (0.38) | KMT2AMEN1MEP1BRAPGEF4LMNA | |
| SCHEMBL3812470 | 0.93 | MEN1 (0.34) | KMT2AMEN1MEP1BRAPGEF4LMNA | |
| SCHEMBL3809686 | 0.93 | MEN1 (0.34) | KMT2AMEN1MEP1BRAPGEF4LMNA | |
| SCHEMBL5153705 | 0.92 | ALDH1A1 (0.33) | KMT2AMEN1MEP1BRAPGEF4LMNA | |
| SCHEMBL20184269 | 0.89 | ALDH1A1 (0.44) | KMT2AMEN1LMNAALDH1A1KDM4E | |
| SCHEMBL27206070 | 0.88 | KDM4E (0.39) | KMT2AMEP1BLMNAALDH1A1KDM4E | |
| SCHEMBL30321034 | 0.87 | PRMT5 (0.42) | KMT2AMEN1LMNAALDH1A1MAPK1 | |
| SCHEMBL32681961 | 0.87 | SLC6A2 (0.37) | KMT2AMEN1MEP1BLMNAALDH1A1 | |
| SCHEMBL4795645 | 0.85 | CA2 (0.39) | KMT2AMEN1LMNACA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3593808-B1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | TRICIDA INC (US) | 2020-12-09 | — | — | EP | claimed |
| EP-3578185-B1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | TRICIDA INC (US) | 2020-08-05 | — | — | EP | claimed |
| EP-3124513-B1 | GRAFT POLYMER AND METHOD FOR PRODUCING SAME | NITTO BOSEKI CO LTD (JP) | 2020-04-22 | — | — | EP | claimed |
| EP-3004451-B1 | A POLYMERIC FILM COATING METHOD ON A SUBSTRATE BY DEPOSITING AND SUBSEQUENTLY POLYMERIZING A MONOMERIC COMPOSITION BY PLASMA TREATMENT | UNIV DEGLI STUDI DI MILANO BICOCCA (IT) | 2018-11-21 | — | — | EP | claimed |
| EP-2687521-B1 | \"Process for the enantioselective synthesis of landiolol\ | PROCOS SPA (IT) | 2015-01-07 | — | — | EP | claimed |
| CN-101981023-A | Process for preparing benzo-fused dioxin derivatives | JANSSEN PHARMACEUTICA NV | 2011-02-23 | — | — | CN | claimed |
| EP-2280951-A2 | PROCESSES FOR THE PREPARATION OF BENZO-FUSED DIOXIN DERIVATIVES | Janssen Pharmaceutica, N.V. (BE) | 2011-02-09 | — | — | EP | claimed |
| WO-2009120192-A2 | PROCESS FOR THE PREPARATION OF BENZO-FUSED HETEROARYL DERIVATIVES | JASSEN PHARMACEUTICA, N.V. (BE) | 2009-10-01 | — | — | WO | claimed |
| US-20090247618-A1 | PROCESS FOR PREPARATION OF BENZO-FUSED HETEROARYL DERIVATIVES | JANSSEN PHARMACEUTICA, N.C. (BE) | 2009-10-01 | — | — | US | claimed |
| EP-0932609-B1 | AZAHETEROCYCLYMETHYL DERIVATIVES OF 2,3,8,9-TETRAHYDRO-7H-1,4-DIOXINO 2,3-e]INDOL-8-ONE | WYETH CORP (US) | 2003-05-14 | — | — | EP | claimed |
| EP-0603404-B1 | PROCESS FOR PRODUCING GLYCIDE DERIVATIVE | MITSUI CHEMICALS INC (JP) | 1999-03-17 | — | — | EP | claimed |
| EP-0767778-B1 | 1-PHENOXY-3-N-ALKYLAMINOPROPAN-2-OL HALOGEN DERIVATIVES USEFUL AS MYOCARDIAL beta ADRENERGIC RECEPTOR MARKERS AND AS beta-BLOCKING AGENTS | CIS BIO INT (FR) | 1998-12-16 | — | — | EP | claimed |
| EP-0467637-B1 | Pyrazolo(1,5-a)pyridine compounds, and production and use thereof | SENJU PHARMA CO (JP) | 1995-10-18 | — | — | EP | claimed |
| EP-0335158-B1 | Nitrogen containing polymeric compounds | BAYER AG (DE) | 1994-07-06 | — | — | EP | claimed |
| US-5202334-A | Pyrazolo[1,5-a]pyridine compounds, and production and use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 1993-04-13 | — | — | US | claimed |
| EP-0467637-A1 | Pyrazolo(1,5-a)pyridine compounds, and production and use thereof | Senju Pharmaceutical Co., Ltd. (JP) | 1992-01-22 | — | — | EP | claimed |
| EP-0335158-A1 | Nitrogen containing polymeric compounds | BAYER AG (DE) | 1989-10-04 | — | — | EP | claimed |
| WO-2022045093-A1 | NOVEL COMPOUND, α-SYNUCLEIN AGGREGATE BINDER, AND USE THEREOF | 国立研究開発法人量子科学技術研究開発機構 | 2022-03-03 | — | — | WO | disclosed |
| EP-0335158-A1 | Nitrogen containing polymeric compounds | BAYER AG (DE) | 1989-10-04 | — | — | EP | disclosed |
| EP-0269258-A2 | Process for the preparation of a pyrrolidinol compound | A.H. ROBINS COMPANY, INCORPORATED (US) | 1988-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247618-A1 | PROCESS FOR PREPARATION OF BENZO-FUSED HETEROARYL DERIVATIVES | CYP3A4, CYP3A5, CYP1A2 | KMT2A 622/4885MEN1 1136/4885MEP1B 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.